Luke Halpern is an assistant editor with Pharmacy Times. Luke wrote for Pharmacy Times in the summer of 2023, and assumed a full-time role in June 2024. His work has been featured in Pharmacy Times and the American Journal of Managed Care. He graduated from the University of Massachusetts, Amherst in May 2024.
FDA Recommends 2025-2026 COVID-19 Vaccines Be Monovalent, Target LP.8.1 Strain
May 27th 2025Following a meeting of the Vaccines and Related Biological Products Advisory Committee, the FDA announced its recommendation of COVID-19 vaccines targeting LP.8.1, a strain of the JN.1 variant that has become dominant in the US.
Read More
FDA to Restrict Future COVID-19 Vaccine Recommendations to Older Adults, High-Risk Groups
May 21st 2025In a major policy shift, officials from the FDA announced a new regulatory framework for COVID-19 vaccinations, prioritizing adults 65 years and older and individuals with serious comorbidities putting them at high risk for severe COVID-19.
Read More
The vaccine, indicated with a restriction on use for those younger than 65 years and without comorbidities, was proven safe and effective in a series of large clinical trials, and marks the first protein-based vaccine to be approved in the United States.
Read More
AAN 2025: Patient Voices Key to Understanding Broader Benefits of Xywav in Sleep Disorders
May 15th 2025Logan Schneider, MD, highlights the importance of integrating patient-reported outcomes into clinical trials to better capture the full therapeutic impact of low-sodium oxybate (Xywav) beyond traditional sleep metrics.
Read More